Spectrum Pharma Inc (SPPI) 6.94 $SPPI
Spectrum Pharmaceuticals Up 35.6% Since SmarTrend Uptrend Call (SPPI)
Comtex SmarTrend(R) - Mon Jun 06, 1:27PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 3 months, Spectrum Pharmaceuticals has returned 35.58% as of today's recent price of $7.24.
SPPI: 6.94 (-0.03)
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2016 Healthcare Conference on June 8th
BusinessWire - Wed Jun 01, 6:00AM CDT
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Jefferies 2016 Healthcare Conference being held at the Grand Hyatt in New York. The Company presentation is on Wednesday, June 8, 2016, at 10:30 AM ET.
SPPI: 6.94 (-0.03)
Uptrend Call Working As Spectrum Pharmaceuticals Stock Rises 39.1% (SPPI)
Comtex SmarTrend(R) - Fri May 27, 1:06PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 3 months, Spectrum Pharmaceuticals has returned 39.14% as of today's recent price of $7.43.
SPPI: 6.94 (-0.03)
Spectrum Pharmaceuticals Shares Up 33.0% Since SmarTrend's Buy Recommendation (SPPI)
Comtex SmarTrend(R) - Thu May 12, 1:09PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 2 months, Spectrum Pharmaceuticals has returned 32.96% as of today's recent price of $7.10.
SPPI: 6.94 (-0.03)
Spectrum Pharma reports 1Q loss
Automated Insights - Thu May 05, 3:25PM CDT
HENDERSON, Nev. (AP) _ Spectrum Pharmaceuticals Inc. (SPPI) on Thursday reported a loss of $9.3 million in its first quarter.
SPPI: 6.94 (-0.03)
Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update
BusinessWire - Thu May 05, 3:00PM CDT
--Poziotinib, a novel pan-HER inhibitor: A Phase 2 trial was initiated and is enrolling breast cancer patients who have failed other HER2-directed therapies.
SPPI: 6.94 (-0.03)
30.3% Return Seen to Date on SmarTrend Spectrum Pharmaceuticals Call (SPPI)
Comtex SmarTrend(R) - Thu May 05, 12:49AM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 2 months, Spectrum Pharmaceuticals has returned 30.34% as of today's recent price of $6.96.
SPPI: 6.94 (-0.03)
Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 113.74 (-1.34), SPPI: 6.94 (-0.03), BIND: 0.40 (-0.01), FOLD: 6.05 (-0.66)
FDA Grants Orphan Drug Exclusivity to EVOMELA(TM) (melphalan) for Injection, Indicated for Multiple Myeloma
BusinessWire - Wed Apr 20, 6:00AM CDT
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted 7 years of Orphan Drug Exclusivity for EVOMELA for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. EVOMELA has also been recently listed in the Orange Book, including two composition of matter patents that do not expire until March 2029.
SPPI: 6.94 (-0.03)
Four Biotech Stocks To Consider As The Sector Breaks Out
ACCESSWIRE - Thu Apr 07, 11:57AM CDT
NEW YORK, NY / ACCESSWIRE / April 7, 2016 / Has biotech finally bottomed? After an 8-month long bear market with biotech stocks losing over 40%, signs of a breakout are now becoming more and more obvious. All eyes are on the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) as the 50 day moving average has been overtaken since the beginning of the month.
VRX: 24.14 (-1.34), CRBP: 2.98 (+0.03), IBB: 267.60 (-5.98), SPPI: 6.94 (-0.03)
Spectrum Pharmaceuticals Up 26.8% Since SmarTrend Uptrend Call (SPPI)
Comtex SmarTrend(R) - Mon Apr 04, 1:01PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 4 weeks, Spectrum Pharmaceuticals has returned 26.78% as of today's recent price of $6.77.
SPPI: 6.94 (-0.03)
Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA(TM) (melphalan) for Injection
BusinessWire - Tue Mar 15, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) of EVOMELA(TM) (melphalan) for use in two indications: 1) as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with MM, and 2) for the palliative treatment of patients with MM for whom oral therapy is not appropriate. This is the first product to be FDA approved for the high-dose conditioning indication in MM. Spectrum plans to launch EVOMELA with its existing sales force.
LGND: 113.74 (-1.34), SPPI: 6.94 (-0.03)
FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA(TM) (melphalan) for Injection
BusinessWire - Tue Mar 15, 6:00AM CDT
--Palliative Treatment of Patients with MM Who Cannot Take Oral Therapy
SPPI: 6.94 (-0.03)
Spectrum (SPPI) Incurs Narrower-than-Expected Loss in Q4
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 10:08AM CST
Spectrum (SPPI) reported a loss of 6 cents per share in the fourth quarter of 2015, narrower than the Zacks Consensus Estimate of a loss of 20 cents.
HZNP: 17.88 (-0.65), SPPI: 6.94 (-0.03), AMAG: 21.04 (-0.82), ANIK: 49.16 (+0.24)
Spectrum Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results and Pipeline Update
BusinessWire - Wed Mar 09, 3:00PM CST
--Poziotinib, a novel pan-HER inhibitor: A Phase 2 trial was initiated in breast cancer patients who have failed other HER2-directed therapies.
SPPI: 6.94 (-0.03)
Spectrum Pharmaceuticals Up 35.6% Since SmarTrend Uptrend Call (SPPI)
Comtex SmarTrend(R) - Mon Jun 06, 1:27PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 3 months, Spectrum Pharmaceuticals has returned 35.58% as of today's recent price of $7.24.
SPPI: 6.94 (-0.03)
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2016 Healthcare Conference on June 8th
BusinessWire - Wed Jun 01, 6:00AM CDT
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Jefferies 2016 Healthcare Conference being held at the Grand Hyatt in New York. The Company presentation is on Wednesday, June 8, 2016, at 10:30 AM ET.
SPPI: 6.94 (-0.03)
Uptrend Call Working As Spectrum Pharmaceuticals Stock Rises 39.1% (SPPI)
Comtex SmarTrend(R) - Fri May 27, 1:06PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 3 months, Spectrum Pharmaceuticals has returned 39.14% as of today's recent price of $7.43.
SPPI: 6.94 (-0.03)
Spectrum Pharmaceuticals Shares Up 33.0% Since SmarTrend's Buy Recommendation (SPPI)
Comtex SmarTrend(R) - Thu May 12, 1:09PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 2 months, Spectrum Pharmaceuticals has returned 32.96% as of today's recent price of $7.10.
SPPI: 6.94 (-0.03)
Spectrum Pharma reports 1Q loss
Automated Insights - Thu May 05, 3:25PM CDT
HENDERSON, Nev. (AP) _ Spectrum Pharmaceuticals Inc. (SPPI) on Thursday reported a loss of $9.3 million in its first quarter.
SPPI: 6.94 (-0.03)
Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update
BusinessWire - Thu May 05, 3:00PM CDT
--Poziotinib, a novel pan-HER inhibitor: A Phase 2 trial was initiated and is enrolling breast cancer patients who have failed other HER2-directed therapies.
SPPI: 6.94 (-0.03)
30.3% Return Seen to Date on SmarTrend Spectrum Pharmaceuticals Call (SPPI)
Comtex SmarTrend(R) - Thu May 05, 12:49AM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 2 months, Spectrum Pharmaceuticals has returned 30.34% as of today's recent price of $6.96.
SPPI: 6.94 (-0.03)
Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 113.74 (-1.34), SPPI: 6.94 (-0.03), BIND: 0.40 (-0.01), FOLD: 6.05 (-0.66)
FDA Grants Orphan Drug Exclusivity to EVOMELA(TM) (melphalan) for Injection, Indicated for Multiple Myeloma
BusinessWire - Wed Apr 20, 6:00AM CDT
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted 7 years of Orphan Drug Exclusivity for EVOMELA for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. EVOMELA has also been recently listed in the Orange Book, including two composition of matter patents that do not expire until March 2029.
SPPI: 6.94 (-0.03)
Four Biotech Stocks To Consider As The Sector Breaks Out
ACCESSWIRE - Thu Apr 07, 11:57AM CDT
NEW YORK, NY / ACCESSWIRE / April 7, 2016 / Has biotech finally bottomed? After an 8-month long bear market with biotech stocks losing over 40%, signs of a breakout are now becoming more and more obvious. All eyes are on the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) as the 50 day moving average has been overtaken since the beginning of the month.
VRX: 24.14 (-1.34), CRBP: 2.98 (+0.03), IBB: 267.60 (-5.98), SPPI: 6.94 (-0.03)
Spectrum Pharmaceuticals Up 26.8% Since SmarTrend Uptrend Call (SPPI)
Comtex SmarTrend(R) - Mon Apr 04, 1:01PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 4 weeks, Spectrum Pharmaceuticals has returned 26.78% as of today's recent price of $6.77.
SPPI: 6.94 (-0.03)
Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA(TM) (melphalan) for Injection
BusinessWire - Tue Mar 15, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) of EVOMELA(TM) (melphalan) for use in two indications: 1) as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with MM, and 2) for the palliative treatment of patients with MM for whom oral therapy is not appropriate. This is the first product to be FDA approved for the high-dose conditioning indication in MM. Spectrum plans to launch EVOMELA with its existing sales force.
LGND: 113.74 (-1.34), SPPI: 6.94 (-0.03)
FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA(TM) (melphalan) for Injection
BusinessWire - Tue Mar 15, 6:00AM CDT
--Palliative Treatment of Patients with MM Who Cannot Take Oral Therapy
SPPI: 6.94 (-0.03)
Spectrum (SPPI) Incurs Narrower-than-Expected Loss in Q4
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 10:08AM CST
Spectrum (SPPI) reported a loss of 6 cents per share in the fourth quarter of 2015, narrower than the Zacks Consensus Estimate of a loss of 20 cents.
HZNP: 17.88 (-0.65), SPPI: 6.94 (-0.03), AMAG: 21.04 (-0.82), ANIK: 49.16 (+0.24)
Spectrum Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results and Pipeline Update
BusinessWire - Wed Mar 09, 3:00PM CST
--Poziotinib, a novel pan-HER inhibitor: A Phase 2 trial was initiated in breast cancer patients who have failed other HER2-directed therapies.
SPPI: 6.94 (-0.03)
